270.26

0.88% -2.39

After Hours: 270.26

Krystal Biotech Inc (KRYS)

Overview News Price History Option Chain Financials Why KRYS Down? Discussions Forecast

Krystal Biotech Inc stock is traded at $270.26, with a volume of 128.79K. It is down -0.88% in the last 24 hours and down -0.69% over the past month. Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Previous Close:

$272.65

Open:

$275.56

24h Volume:

128.79K

Relative Volume:

0.47

Market Cap:

$7.84B

Revenue:

$290.51M

Net Income/Loss:

$89.16M

P/E Ratio:

90.39

EPS:

2.99

Net Cash Flow:

$119.18M

1W Performance:

+0.98%

1M Performance:

-0.69%

6M Performance:

+88.18%

1Y Performance:

+78.60%

1-Day Range:

$269.40

$275.56

1-Week Range:

$260.03

$280.00

52-Week Range:

$122.80

$295.98

Krystal Biotech Inc Stock (KRYS) Company Profile

Name

Krystal Biotech Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(412) 586-5830

Address

2100 WHARTON STREET, PITTSBURGH, PA

Employee

275

Twitter

@KrystalBiotech

Next Earnings Date

2024-11-04

Latest SEC Filings

KRYS's Discussions on Twitter

Compare KRYS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KRYS Krystal Biotech Inc	270.26	7.91B	290.51M	89.16M	119.18M	2.99
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-06-26	Upgrade	Citigroup	Neutral → Buy
Mar-05-25	Initiated	Jefferies	Buy
Aug-06-24	Downgrade	Citigroup	Buy → Neutral
Nov-20-23	Initiated	Goldman	Buy
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-12-23	Initiated	Citigroup	Buy
Sep-07-23	Initiated	Berenberg	Buy
Apr-18-23	Initiated	Stifel	Buy
Feb-28-23	Upgrade	Goldman	Neutral → Buy
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-18-22	Initiated	BofA Securities	Buy
Jul-20-21	Upgrade	Goldman	Neutral → Buy
Sep-18-20	Initiated	B. Riley FBR	Buy
Jun-04-20	Initiated	Evercore ISI	Outperform
Sep-24-19	Initiated	Goldman	Neutral
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jun-24-19	Reiterated	Chardan Capital Markets	Buy
Jun-24-19	Reiterated	H.C. Wainwright	Buy
May-30-19	Initiated	Guggenheim	Buy
Sep-11-18	Initiated	Cantor Fitzgerald	Overweight

View All

Krystal Biotech Inc Stock (KRYS) Latest News

09:00 AM

Alps Advisors Inc. Decreases Stock Holdings in Krystal Biotech, Inc. $KRYS - MarketBeat

Feb 11, 2026

Krystal Biotech co-founder makes Forbes 250 innovators list - Mugglehead Investment Magazine

Feb 11, 2026

Feb 10, 2026

Krystal Biotech wins FDA RMAT status for lung cancer therapy - MSN

Feb 10, 2026

Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update (NASDAQ:KRYS) - Seeking Alpha

Feb 10, 2026

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 - The Manila Times

Feb 10, 2026

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 - GlobeNewswire Inc.

Feb 10, 2026

FDA grants RMAT designation to Krystal Biotech’s lung cancer therapy By Investing.com - Investing.com South Africa

Feb 10, 2026

Feb 09, 2026

Krystal Biotech (KRYS) Gains FDA RMAT Status for Innovative Lung Cancer Therapy - GuruFocus

Feb 09, 2026

Krystal Biotech wins FDA RMAT status for cancer drug (KRYS) - Seeking Alpha

Feb 09, 2026

Krystal Biotech Receives FDA RMAT Designation for KB707 - Intellectia AI

Feb 09, 2026

Krystal Biotech Says US FDA Grants Regenerative Medicine Advanced Therapy Designation to Lung Cancer Treatment - marketscreener.com

Feb 09, 2026

FDA grants RMAT designation to Krystal Biotech’s lung cancer therapy - Investing.com

Feb 09, 2026

Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of ... - Caledonian Record

Feb 09, 2026

Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer - The Manila Times

Feb 09, 2026

FDA backs KB707 lung cancer immunotherapy with RMAT designation - Stock Titan

Feb 09, 2026

Feb 07, 2026

Krystal Biotech (NASDAQ:KRYS) Stock Rating Lowered by Zacks Research - MarketBeat

Feb 07, 2026

Feb 06, 2026